title: The preventive effect of tamsulosin on voiding dysfunction after prostate biopsy: a prospective, open-label, observational study.
abstract: OBJECTIVE
  To evaluate the association of prostate biopsy with voiding impairment and to investigate whether tamsulosin treatment given before prostate biopsy could improve voiding dysfunction after the procedure.
  
  
  METHODS
  The study included 88 consecutive patients who underwent transrectal ultrasound-guided prostate biopsy without prior BPH medication and were prospectively randomized. Of these 88 patients, 44 patients underwent prostate biopsy only without tamsulosin treatment and served as the control group. The remaining 44 patients were treated with tamsulosin (0.2 mg daily) beginning the day before the biopsy procedure for 7 days. The International Prostate Symptom Score (IPSS) was recorded in all patients before the procedure and on postbiopsy day 7. Maximal flow rate (Q(max)) and postvoid residual urine volume were recorded in all patients before the procedure and on postbiopsy days 1 and 7.
  
  
  RESULTS
  No difference was found in baseline characteristics between the two groups. The IPSS (total, storage, and voiding symptom) was not significantly changed after biopsy in both groups. In the control group, the postvoid residual urine volume was increased on postbiopsy days 1 (P < 0.05) and 7, and the Q(max) was significantly decreased on postbiopsy day 7 compared with the baseline value (P < 0.05). In the tamsulosin group, Q(max) was significantly increased on postbiopsy days 1 and 7 (P < 0.01). The postvoid residual urine volume was not increased on postbiopsy days 1 and 7. Acute urinary retention after the biopsy procedure did not develop in any of the patients (0%) in the tamsulosin group, but it developed in two patients (4.5%) of the control group.
  
  
  CONCLUSIONS
  The results of our study show that prostate biopsy leads to objective voiding impairment. Therefore, the use of alpha-1 blocker tamsulosin before biopsy in patients without prior BPH medication may decrease this morbidity.
authors: Department of Urology, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun, 519-763, Republic of Korea.
authors: Seung Jun
authors: SJ
authors: Chung
authors: Seung Il
authors: SI
authors: Jung
authors: Ji Won
authors: JW
authors: Ryu
authors: Eu Chang
authors: EC
authors: Hwang
authors: Dong Deuk
authors: DD
authors: Kwon
authors: Kwangsung
authors: K
authors: Park
authors: Jin Woong
authors: JW
authors: Kim
mesh_terms: D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use; D061765:Endoscopic Ultrasound-Guided Fine Needle Aspiration / Q000009:adverse effects; D059411:Lower Urinary Tract Symptoms / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology; D013449:Sulfonamides / Q000627:therapeutic use; D000077409:Tamsulosin; D016055:Urinary Retention / Q000209:etiology / Q000517:prevention & control; D014563:Urodynamics
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D013449:Sulfonamides; D000077409:Tamsulosin